Ritlecitinib

Status:: Red
Decision Date:: April 2024

Comments

RED:

NICE TA958. For treating severe alopecia areata in people 12 years and over. ICB commissioned.

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)